Literature DB >> 14662274

On the use and utility of the Weibull model in the analysis of survival data.

Kevin J Carroll1.   

Abstract

In the analysis of survival data arising in clinical trials, Cox's proportional hazards regression model (or equivalently in the case of two treatment groups, the log-rank test) is firmly established as the accepted, statistical norm. The wide popularity of this model stems largely from extensive experience in its application and the fact that it is distribution free-no assumption has to be made about the underlying distribution of survival times to make inferences about relative death rates. However, if the distribution of survival times can be well approximated, parametric failure-time analyses can be useful, allowing a wider set of inferences to be made. The Weibull distribution is unique in that it is the only one that is simultaneously both proportional and accelerated so that both relative event rates and relative extension in survival time can be estimated, the latter being of clear clinical relevance. The aim of this paper is to examine the use and utility of the Weibull model in the analysis of survival data from clinical trials and, in doing so, illustrate the practical benefits of a Weibull-based analysis.

Entities:  

Mesh:

Year:  2003        PMID: 14662274     DOI: 10.1016/s0197-2456(03)00072-2

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  51 in total

1.  Forecast of future premature mortality as a result of trends in obesity and smoking: nationwide cohort simulation study.

Authors:  Kristian Neovius; Finn Rasmussen; Johan Sundström; Martin Neovius
Journal:  Eur J Epidemiol       Date:  2010-07-03       Impact factor: 8.082

Review 2.  Do immune checkpoint inhibitors need new studies methodology?

Authors:  Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Parametric regression model for survival data: Weibull regression model as an example.

Authors:  Zhongheng Zhang
Journal:  Ann Transl Med       Date:  2016-12

4.  Assessing the fit of parametric cure models.

Authors:  E Paul Wileyto; Yimei Li; Jinbo Chen; Daniel F Heitjan
Journal:  Biostatistics       Date:  2012-11-28       Impact factor: 5.899

5.  Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey.

Authors:  David I Rosenthal; Abdallah S R Mohamed; Randal S Weber; Adam S Garden; Parag R Sevak; Merril S Kies; William H Morrison; Jan S Lewin; Adel K El-Naggar; Lawrence E Ginsberg; Esengul Kocak-Uzel; K Kian Ang; Clifton David Fuller
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

6.  Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.

Authors:  Stefan Michiels; Richard F Potthoff; Stephen L George
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

7.  Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer.

Authors:  Thomas E Delea; Carol Hawkes; Mayur M Amonkar; Konstantinos Lykopoulos; Stephen R D Johnston
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

8.  Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective.

Authors:  Marcio Machado; Thomas R Einarson
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-11-13

9.  Onset of breast development in a longitudinal cohort.

Authors:  Frank M Biro; Louise C Greenspan; Maida P Galvez; Susan M Pinney; Susan Teitelbaum; Gayle C Windham; Julianna Deardorff; Robert L Herrick; Paul A Succop; Robert A Hiatt; Lawrence H Kushi; Mary S Wolff
Journal:  Pediatrics       Date:  2013-11-04       Impact factor: 7.124

10.  Use of short message service (SMS) to improve malaria chemoprophylaxis compliance after returning from a malaria endemic area.

Authors:  Lénaïck Ollivier; Olivier Romand; Catherine Marimoutou; Rémy Michel; Corinne Pognant; Alain Todesco; René Migliani; Dominique Baudon; Jean-Paul Boutin
Journal:  Malar J       Date:  2009-10-23       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.